Careers
Contact Us

Company
Pipeline
Disease States
Science
Investors

Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine

Posted March 4, 2019 by CognitionDev

filed under: Nasdaq

In the News

Jun 26, 2020

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation

Click to view full release

Jun 4, 2020

Axsome Therapeutics to Present at Upcoming Investor Conferences

Click to view full release

May 29, 2020

Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting

Click to view full release

See All News

© 2020 Axsome Therapeutics, Inc. All rights reserved. 200 Broadway, 3rd Floor, New York, NY 10038 info@axsome.com

This modal has no inner div